CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 63 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,756,353 | -30.4% | 263,690 | +1.4% | 0.00% | -50.0% |
| Q2 2023 | $8,268,579 | +43.8% | 260,100 | +10.4% | 0.00% | +100.0% |
| Q1 2023 | $5,748,674 | -22.4% | 235,698 | +0.4% | 0.00% | -50.0% |
| Q4 2022 | $7,405,971 | +15.8% | 234,812 | +3.7% | 0.00% | 0.0% |
| Q3 2022 | $6,398,000 | +16.0% | 226,405 | +8.6% | 0.00% | +100.0% |
| Q2 2022 | $5,514,000 | -61.3% | 208,542 | -48.8% | 0.00% | -66.7% |
| Q1 2022 | $14,254,000 | -0.2% | 407,163 | -7.5% | 0.00% | 0.0% |
| Q4 2021 | $14,276,000 | +14.3% | 440,333 | +4.1% | 0.00% | +50.0% |
| Q3 2021 | $12,485,000 | +27.4% | 423,161 | +10.6% | 0.00% | 0.0% |
| Q2 2021 | $9,800,000 | -14.1% | 382,491 | -54.0% | 0.00% | 0.0% |
| Q1 2021 | $11,407,000 | +3077.4% | 830,788 | +3739.7% | 0.00% | – |
| Q4 2020 | $359,000 | – | 21,637 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,199,729 | $1,314,160,084 | 42.08% |
| Perceptive Advisors | 10,088,385 | $220,229,445 | 7.35% |
| Finepoint Capital LP | 563,345 | $12,297,821 | 6.12% |
| Affinity Asset Advisors, LLC | 685,061 | $14,954,882 | 4.21% |
| Paradigm Biocapital Advisors LP | 2,532,972 | $55,294,779 | 3.75% |
| Logos Global Management LP | 700,000 | $15,281,000 | 2.04% |
| Artal Group S.A. | 1,638,858 | $35,776 | 1.53% |
| Rock Springs Capital Management LP | 2,529,116 | $55,210,602 | 1.48% |
| GREAT POINT PARTNERS LLC | 215,000 | $4,693,450 | 0.86% |
| Frazier Life Sciences Management, L.P. | 393,000 | $8,579,190 | 0.57% |